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Heterogeneous shedding of 
influenza by human subjects and its 
implications for epidemiology and 
control
Laetitia Canini1, Mark E. J. Woolhouse1, Taronna R. Maines2 & Fabrice Carrat3,4,5
Heterogeneity of infectiousness is an important feature of the spread of many infections, with 
implications for disease dynamics and control, but its relevance to human influenza virus is still 
unclear. For a transmission event to occur, an infected individual needs to release infectious particles 
via respiratory symptoms. Key factors to take into account are virus dynamics, particle release in 
relation to respiratory symptoms, the amount of virus shed and, importantly, how these vary between 
infected individuals. A quantitative understanding of the process of influenza transmission is relevant to 
designing effective mitigation measures. Here we develop an influenza infection dynamics model fitted 
to virological, systemic and respiratory symptoms to investigate how within-host dynamics relates 
to infectiousness. We show that influenza virus shedding is highly heterogeneous between subjects. 
From analysis of data on experimental infections, we find that a small proportion (<20%) of influenza 
infected individuals are responsible for the production of 95% of infectious particles. Our work supports 
targeting mitigation measures at most infectious subjects to efficiently reduce transmission. The 
effectiveness of public health interventions targeted at highly infectious individuals would depend on 
accurate identification of these subjects and on how quickly control measures can be applied.
Heterogeneity of infectiousness is an important feature of the spread of many infections, such as E. coli O157, 
paratuberculosis or salmonella and has been shown to have implications for disease dynamics and control1. Lau 
et al. showed evidence of heterogeneity in viral shedding in symptomatic patients naturally infected by influenza 
A virus2. However, they could not document the overall time course of the infection as the time of exposure is 
unknown for naturally infected cases, so the implications of heterogeneous infectiousness for the epidemiology 
and control of influenza remain unclear.
For a transmission event to occur, an influenza infected individual needs to release infectious particles via 
respiratory symptoms. Key factors to take into account are virus dynamics, virus spreading in relation to res-
piratory symptoms, the amount of virus shed and, importantly, how these vary between infected individuals3,4. 
Understanding influenza transmission process and the factors associated with increased infectiousness is relevant 
to the implementation of effective mitigation measures5.
Influenza within-host dynamics modelling allows a quantitative description of the infection and/or symptoms 
dynamics and has received increasing attention over the past decade6–14. We extend a previously published model 
describing viral kinetics (VK) and symptoms dynamics (SD)6 to include the dynamics of respiratory symptoms. 
The model is fitted to virological, systemic and respiratory symptoms and is used to investigate how within-host 
dynamics relates to infectiousness.
Using a mathematical modelling approach, we aim to link viral shedding to influenza within-host dynamics 
and to identify parameters associated with heterogeneity of infectiousness.
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Material and Methods
Data. We used data from the control arm of five studies conducted between 1993 and 1997 comprising 56 
healthy volunteers experimentally infected with influenza virus. These studies were randomized, double-blind, 
placebo-controlled registration studies of zanamivir treatment of H1N1 influenza virus (NAIA1001, NAIA1002, 
NAIA1003, NAIA1004 and NAIA1010). All were approved by ethics committees, and the volunteers gave their 
written informed consent. Volunteers were eligible for these studies if they were Caucasian men or women aged 
from 18 to 40 years, with serum hemagglutinin antibody titres of < 1:8 to the relevant virus strains. They were 
non-smokers or smoked an average of less than 10 cigarettes per day and agreed not to smoke for the duration of 
the isolation period. They were judged to be healthy based on medical records, physical examination and labora-
tory investigations6.
The volunteers under placebo were challenged at 08:00 with 105 median tissue culture infective doses (TCID50) 
of influenza A/Texas/91/36 (H1N1) virus intranasally and were monitored daily for the following 7 or 8 days. 
A sample for viral shedding kinetics analysis was taken from each volunteer 8 or 9 times. In four studies (48 
subjects), sample collection took place at 08:00 on day 0 (D0) before the challenge, and then on D1, D2, D3, D4, 
D5, D6, D7, and D8; no D8 sample was collected in the fifth study (8 subjects). The following symptoms were 
noted: earache, runny nose, sore throat, coughing, sneezing, breathing difficulties, muscle ache, fatigue, headache, 
feverish feeling, hoarseness, and chest discomfort. The intensity of each symptom was scored by the patient from 
0 (none) to 3 (severe). Symptoms data were collected twice a day, at 08:00 and 20:00 on the same days as the viral 
titre samples6.
We used the systemic symptoms score constructed in a previous study (i.e. the sum of the scores for feverish 
feeling, headache, fatigue and muscular fever)6. We built similarly a respiratory symptom score by summing the 
scores for runny nose, sore throat, coughing and sneezing. This led to symptoms scores ranging between 0 and 
12. We focused on these symptoms as they were the most frequent and also the most likely to spread virus in the 
environment of the infected subjects.
Model. We adapted the within-host dynamic model previously developed by Canini and Carrat6 to take into 
account respiratory symptoms dynamics. This model described influenza viral kinetics as:
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In this model as represented in Fig. 1, infectious viruses, V, infect target cells, T, at rate β and are cleared at rate c. 
The infected cells, I, produce virus at rate p and are lost at rate δ. The infected cells induce the production of local 
pro-inflammatory cytokines, FL, at rate γ. The local pro-inflammatory cytokines decrease the virus production 
rate, p, with an effect ψ, are cleared at rate αL and induce the production of systemic pro-inflammatory cytokines, 
FS, at rate ρ. As the cytokines levels were not measured, we set their dimension to F. Systemic pro-inflammatory 
cytokines are cleared at rate αS and induce the activation of the cytotoxic activity, N. Cytotoxic activity, whose 
dimension was set to cell−1.d−1, is induced at rate k by systemic pro-inflammatory cytokines and removes infected 
cells at rate η. We set k to 1 F−1. cell−1, d−2, without loss of generality, as this changes only the units in which 
cytotoxic activity is measured. A conversion factor σ is needed for the conversion from infectious virus, V in our 
model, to TCID50/mL as measured by the experimental data15. Here we set σ = 0.69 TCID50/mL. cell−1 which 
is consistent with 1 mL virus stock having half the number of plaque forming units (PFUs) as the TCID50. The 
detailed dimension analysis is shown in supplementary material.
The initial values for the different compartments were: T0 = 4× 108 cells16, I0 = FL,0 = FS,0 = N0 = 0 as 
we assumed that there were no infected cells and the innate immune response (i.e. systemic and local 
pro-inflammatory cytokines, and cytotoxic activity) was not activated. T0 was determined by Baccam et al. as the 
number of epithelial cells lining the nasal turbinates of the respiratory tract16. V0 was estimated as a parameter. 
We did not assume that V0 was the inoculated dose as we have no information concerning the quantity of virus 
remaining in the nose.
Local and systemic pro-inflammatory cytokines levels, particularly IFN-α and IL-6 correlate with respira-
tory and systemic symptom dynamics17–21. We therefore decided to use the symptom scores as surrogate for 
pro-inflammatory cytokine levels. The respiratory symptoms were modelled as:
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R(t) represents the respiratory symptom score at time t and Rmax = 12 is the upper limit of the respiratory 
symptom score scale. We computed the systemic symptom score in a similar fashion, as a function of the level of 
systemic cytokines FS(t) and the upper limit of the systemic symptom score scale, Smax = 12.
Parameter estimation. Nonlinear mixed-effect models were used in order to take into account the 
inter-individual variability (IIV) and to compute individual parameters (see Supplementary Material). Each 
parameter is described by a fixed effect determining the average value in the population and a random effect deter-
mining the IIV. Additionally, we estimated the full variance-covariance matrix for random effect and used the 
normalized covariance to describe the correlations between the parameters distributions. Population parameters 
were estimated by likelihood maximization using the stochastic approximation of the expectation-maximization 
(SAEM) algorithm, implemented in MONOLIX 4.3.2 (http://www.lixoft.eu/). Individual parameters are com-
puted as empirical Bayes estimates. We simultaneously fitted the viral titre data, the systemic symptom score data 
and the respiratory symptom score data.
When testing different models, we chose the model providing the smallest Bayesian information criteria 
(BIC)22. We performed a practical identifiability analysis as suggested by Brun et al.22, using the package FME 
implemented in R23.
Natural history parameters. We computed the population and individual infectiousness and other epide-
miological parameters (incubation period and duration of symptomatic phase) to predict how these parameters 
would vary within a large population. We used the estimated population VK/SD parameters to compute the 
population epidemiological parameters. We simulated 1,000 subjects by drawing 1,000 sets of individual VK/
SD parameters from the distributions estimated above, taking into account the correlation between the different 
distributions. We then simulated the individual viral kinetics, systemic and respiratory symptoms dynamics. 
We used these simulations to predict how individual infectiousness varies in time. We present the median and 
inter-quartile range (Q1-Q3) for the parameters computed from the simulations.
We assumed that infectiousness is a function of viral titre and respiratory symptoms. We adapted Chen 
et al.’s24 expression for the production of infectious particles as J(t) = V(t)(b+ sR(t)), where b is the baseline infec-
tiousness in the absence of respiratory symptoms and s the slope factor. Indeed, infectious particles can also be 
Figure 1. Schematics of the within-host dynamic model of influenza infection. Infectious viruses, V, infect 
target cells, T, at rate β and are cleared at rate c. The infected cells, I, produce virus at rate p and are lost at rate 
δ. The infected cells induce the production of local pro-inflammatory cytokines, FL, at rate γ. The local pro-
inflammatory cytokines decrease p by a factor ψ, are cleared at rate αL and induce the production of systemic 
pro-inflammatory cytokines, FS, at rate α. Systemic pro-inflammatory cytokines are cleared at rate αS and 
induce the activation of the cytotoxic activity, N, at rate k. Cytotoxic activity removes infected cells at rate η. The 
respiratory and systemic symptoms were used as proxy for FL and FS, respectively.
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produced during normal breathing3. R(t) and V(t) are the individual respiratory symptom score and viral titre at 
time t predicted by the within-host model.
For symptomatic subjects, we computed the incubation period as the time from inoculation to reach a total 
symptom score (i.e. the sum of both respiratory and systemic symptom score) of 1, 2, 3 or 4 and the duration of 
the symptomatic phase as the time during which the total symptom score is above 1, 2, 3 or 4.
Results
Description of the experimental inoculation data. 56 volunteers were included in the control arm 
of the 5 studies of antiviral drug trial and received only placebo treatment. 12 of these subjects did not have a 
virus-positive sample on any occasion after the challenge and were therefore excluded from the analysis as unin-
fected. Of the 44 subjects shedding influenza virus, 9 did not report systemic symptoms on any occasion after the 
challenge and 4 of these did not report respiratory symptoms either; these 4 subjects were therefore considered 
as asymptomatic. The peak for total symptom (i.e. the sum of systemic and respiratory symptoms scores) had a 
median score of 6 and ranged between 0 and 20, for a scale ranging between 0 and 24.
Time courses of virus titres and symptoms scores are summarized in Fig. 2A,B and Table 1. The distribution 
of the maximal total symptom score in Fig. 2C. Figure 2D shows that on average the area under viral titre curve 
(AUCV) is similar when the maximal total symptom score is above 2 and is above 3-fold higher than in patients 
with maximal total symptom score ≤ 1. For subject with maximal total symptom score ≤ 1, the median AUCV is 
1.58 log10 TCID50/mL (Q1-Q3: 1.24–2.14) whereas for subjects with maximal total symptom score above 2, the 
median AUCV is 4.76 log10 TCID50/mL (Q1-Q3: 4.09–5.52).
S
R
V
inoculation 1 2 3 4 5 6 7 8
Time (dpi)
A
0
2
4
6
8
inoculation 1 2 3 4 5 6 7 8
Onset of viral shedding (dpi)
Sy
m
pt
om
 o
ns
et
 (d
pi)
B
0.0
2.5
5.0
7.5
10.0
12.5
0 5 10
maximal total symptom score
N
um
be
r o
f s
ub
jec
ts
C
2
4
6
0 1 2 3 4 5 6 7 8 9 10 11 12
maximal total symptom score
AU
C 
of
 v
ira
l t
itr
e 
cu
rv
e
 
 
(lo
g1
0 T
CI
D5
0/m
L)
D
Figure 2. (A) Average observed dynamics for viral load (V), respiratory symptoms (R) and systemic symptoms 
(S). Each segment starts at the median onset of V, R or S and ends when V, R or S is undetectable or not 
reported. The dot represents the average time of maximal value, tmax. (B) Relationship between the symptom 
onset (orange dot for respiratory symptoms, blue triangle for systemic symptoms) and the onset of viral 
shedding. Viral shedding onset is defined as the time between inoculation and the first sample above the limit of 
detection. (C) Distribution of the maximal total symptom scores. (D) Distribution of AUCV (the area under the 
viral titre curve) depending on the maximal total symptom scores.
Onset (dpi) End (dpi)
Time of peak 
(dpi) Peak value
Number of 
subjects
Viral titre 2.0 [1.0–2.0] 5.0 [4.0–7.0] 3.0 [2.0 − 3.5] 4.6* [3.2–5.8] 44
Respiratory symptoms 2.0 [1.0–2.5] 6.0 [4.5–8.0] 4.0 [3.0–5.5] 3.0 [2.0–4.0] 40
Systemic symptoms 1.8 [0.5–2.5] 5.0 [3.4–6.1] 3.4 [2.5–5.1] 3.0 [1.8–4.3] 35
Table 1.  Dynamics of observed viral titre, respiratory symptoms and systemic symptoms. Results are 
presented as median and interquartile range [IQR]. Dpi: days post infection. *in log10 TCID50/mL.
www.nature.com/scientificreports/
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Viral kinetics/symptoms dynamics: Parameter estimates and fits. Guided by the practical identifi-
ability analysis, we fixed three parameters, V0, δ and c (Supplementary Information, Fig. S1). Parameters estimates 
are presented in Table 2. The model provides good fits to virus titre, systemic symptom score and respiratory 
symptom score (Fig. 3B and S2 A–C) and the goodness of fit plots are satisfactory (Fig. S3). The model predicts 
that the average virus titre increases sharply to a peak at 2.5 dpi and is then cleared at ~4.8 dpi (Fig. 4A). The local 
and systemic cytokines levels are predicted to increase until 2.8 dpi and to be cleared at ~10 dpi. Finally, the model 
predicts that the cytotoxic activity increases slowly until ~10 dpi (Fig. 4B).
Population parameters estimates are presented in Table 2 and individual parameter estimates in Table S1. Most 
parameters are accurately estimated with a relative standard error (i.e. the ratio of the standard error divided by 
the average value) < 40%. All estimated parameters except p, the virus production rate, show inter-individual 
variability > 100%.
On average, the subjects shedding more virus have more symptoms. Indeed, the area under the viral titre 
curve (AUCV) and the area under the total symptom curve (AUCS) are positively correlated (Spearman’s rank 
correlation: 0.52, p-value = 0.0003) and the maximal total symptom score and the maximal viral titre are also 
positively correlated (Spearman’s rank correlation: 0.64, p-value < 0.0001). This shows that viral titre and total 
symptom score are correlated.
Natural history parameters. Asymptomatic subjects. From the simulations of 1000 subjects, we pre-
dict that 30.1 to 67.4% of subjects are asymptomatic or paucisymptomatic, when we set the maximal symptom 
score threshold between 1 and 4. For the symptomatic subjects, the incubation period lasts on average 1.9 to 
2.4 days and subjects exhibit symptoms for an average of 1.5 to 2.4 days, depending on the threshold (Table 3). 
Symptomatic subjects are 7.4- to 7.8-fold (Wilcoxon test, p-value < 0.0001, for all thresholds) more infectious 
than asymptomatic subjects. We also find that all parameters are significantly different between symptomatic and 
asymptomatic. For a maximal total symptom threshold set to 2, infectivity, β, is 2.3-fold higher; virus production 
rate, p, 2.1-fold higher, effect of pro-inflammatory cytokines on virus production, ψ, 2.9-fold higher, cytotoxicity, 
η, 5.5-fold smaller, local cytokine production rate, ρ, 2.4-fold higher, local cytokine clearance, αL, 3.3-fold smaller, 
systemic cytokines production, γ, 2.5-fold smaller and systemic cytokine clearance, αS, 3.1-fold higher in sympto-
matic than in asymptomatic. The increased cytotoxicity induces a rapid halt in the virus life-cycle, which reduces 
the subsequent inflammation responsible for symptoms.
The peak of infectiousness occurs 1.5 to 2.2 days later in asymptomatic subjects than in symptomatic subjects.
Highly infectious subjects. We predict from our model fits that a limited number of subjects are producing the 
great majority of infectious particles. Indeed, 5/44 and 7/44 shedding subjects were responsible for 90 and 95% of 
infectiousness, respectively (Fig. 3A). We tested several models for the infectiousness, with different values for b 
and s. These subjects were the most infectious with the different values of b and s (Fig. S4).
From the 1000 simulated subjects, we predict that 10.9% and 18.2% of the subjects are responsible for 90 and 
95% of the total population infectiousness, respectively. Interestingly, our model also predicts that 19% and 20% 
of these most infectious subjects have symptom score ≤ 2 and could therefore be considered as asymptomatic. 
This raises the question of the identification of the most infectious subjects.
Parameter Description Unit
Population 
estimate (rse %) IIV % (rse %)
V0 Initial viral load TCID50/mL 0.5 (− ) —
β Infectivity rate (TCID50/mL)−1 d−1 1.4*10−8 (26) 140 (15)
δ Infected cell mortality rate d−1 0.5 (− ) —
p Virus production rate (TCID50/mL). d−1. Cell−1 10.4 (14) 72 (16)
σ Conversion factor from infectious virus into TCID50/mL
TCID50/mL. Cell−1 0.69 (− ) —
ψ Local cytokine effect F−1 8.1 (42) 243 (13)
η Cytotoxic activity — 221 (32) 188 (13)
c Free virus clearance rate d−1 1.0 (− ) —
αL Local cytokine clearance rate F d−1 1.56 (20) 117 (13)
αS Systemic cytokine clearance rate d−1 11.0 (34) 118 (28)
γ Local cytokine production rate F. Cell−1. d−1 2.2*10-5 (80) 497 (12)
ρ Systemic cytokine production rate F−1 8.19 (38) 149 (24)
Table 2.  Viral kinetics and symptoms dynamics parameter estimates. Population estimate indicates the 
average value of the fixed effect, for each parameter. Inter-individual variability (IIV) indicates the average 
value of the random effect, for each parameter. The relative standard error (rse) is the ratio of the standard error 
divided by the average value and is computed for each population estimate and IIV. The symbol ‘–’ is used when 
parameters were fixed. d indicates days. The correlation parameters are shown in the Table S2. The additive 
error terms are a1 = 0.971 log10 TCID50/mL for viral titre, a2 = 0.65 for systemic symptom score and a3 = 0.71 for 
respiratory symptom score.
www.nature.com/scientificreports/
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Four parameters are significantly (p < 0.0001, Spearman correlation) correlated with infectiousness (i.e. AUC 
of J(t)): the virus production rate, p, the cytotoxic activity, η, local cytokine clearance rate, αL, and local cytokine 
production rate, γ.
Discussion
Understanding the temporal dynamics of influenza infectiousness and the factors driving it is relevant to under-
standing influenza epidemiology and designing effective mitigation measures. The parameter estimates and 
predictions from our model are broadly consistent with previous findings. Asymptomatic infections have been 
estimated to account for 30–77% of seasonal influenza cases19,25,26. The wide range of estimates can be explain by 
the threshold used to detect symptomatic subjects. Indeed we predict that depending on the threshold used, the 
proportion of asymptomatic subjects in a given sample varies between 30.1 and 67.4%. Most of the estimated 
parameters are 2.1 to 5.5 fold different between symptomatic and asymptomatic subjects, suggesting that symp-
toms and infectiousness are associated with complex inflammatory mechanisms. Other host and virus factors can 
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Figure 3. Infectiousness. (A) Cumulative infectiousness (percent) for subjects (N = 44) ordered from highest 
to lowest estimated values of infectiousness. (B) Individual fits for the viral titre (blue), systemic symptoms 
(green) and respiratory symptoms (red) for the 9 most infectious subjects.
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also play a role such as the age or virus strain27. Children are more prone to be infected than any age group during 
seasonal influenza epidemics and to develop severe case or complications28 whereas the majority of deaths due to 
influenza are observed in elderly in developed countries29.
Our predicted incubation period of ~2.0 days is close to that found by Lessler et al.30 who estimated the 
median influenza A incubation period is at 1.4 days (Q1-Q3: 1.1–1.9 days) from experimental and observational 
studies. Our predicted duration of symptomatic phase of 1.5–2.4 days is shorter than previously published dura-
tion of illness of 4.5–5.0 days in A/H1N1 experimentally infected patients25.
Using our model to predict infectiousness, we show high heterogeneity in infectiousness. Indeed, our model 
predicts that 10.9% and 18.2% of the infected subjects are responsible for 90% and 95% of infectious particles 
produced, respectively. This heterogeneity in infectiousness adds another level of heterogeneity for influenza 
transmission, in addition to population structure31 and contacts32.
Matthews et al.1 showed that control measures targeting high shedders could be effective strategies to reduce 
E. coli O157 transmission in cattle. Whereas in E. coli O157, there is a bimodal distribution of shedding rates33,34, 
for other infections such as Salmonella, this is not the case, although shedding rates are highly heterogene-
ous35. We did not identify a bimodal distribution for infectiousness produced in the present work (see Fig. 4A). 
However, the high degree of heterogeneity of viral shedding implies that targeting the most infectious subjects 
would have disproportionate benefits. We also predict that, even though on average symptom score is associ-
ated with infectiousness, up to 20% of the most infectious subjects are asymptomatic or paucisymptomatic. 
Consequently, this suggest that highly infectious subjects could remain undetected and would therefore be diffi-
cult to target for mitigation measures.
Our study has two main limitations. First the VK and SD data come from experimental infections with a single 
viral strain of a homogenous population of healthy volunteers with low influenza antibody titres. The applicability 
of our model to natural infection in adults depends on the pathogenicity of the viral strain as well as pre-existing 
immunity associated with past influenza exposure and vaccination. Moreover, increased attack rate of influenza 
among children may reflect their higher susceptibility and infectiousness36,37. To describe the variability of shed-
ding patterns in the general population, it would therefore be necessary to adapt the model to take into account 
how the VK parameters changes with age. Second, in our model, the different pro-inflammatory cytokines (inter-
ferons, interleukins, TNF) are represented by a single variable, as we did not have data to distinguish them. With 
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Figure 4. Influenza infection dynamic curves. (A) Population fits for VK (black), respiratory symptoms (blue) 
and systemic symptoms (red). (B) Average predictions for local cytokines (purple line), systemic cytokines 
(orange line) and cytotoxic activity (green) line. Cytokine dynamics were scaled to show the relative proportions 
of local and systemic cytokines.
Threshold
Proportion of asymptomatic 
or paucisymptomatic (%)
Incubation period 
(days) [Q1-Q3]
Duration of symptomatic 
phase (days) [Q1-Q3]
1 30.1 2.0 [1.4–2.8] 2.4 [1.4–4.5]
2 45.0 2.0 [1.5–2.8] 1.9 [1.0–3.6]
3 57.6 2.4 [1.7–4.2] 1.7 [0.9–3.3]
4 67.4 1.9 [1.4–2.6] 1.5 [0.8–3.1]
Table 3.  Proportion of asymptomatic or paucisymptomatic, incubation period and duration of 
symptomatic phase in 1,000 simulated subjects. Parameters were drawn from the correlated distribution of 
individual parameter. The threshold of total symptom score has been set to 1, 2, 3 or 4. The total symptom score 
scale ranges from 0 to 24.
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the addition of such data, we could provide more refined models for the interaction between the virus and the 
host and possibly identify more precisely the biomarkers associated with increased infectiousness. If informative 
biomarkers were identified, highly infectious subjects could be preferentially targeted for interventions. Second, 
symptom scores were self-reported and data describing thoroughly the number of coughs or sneezes were not 
available. Particles count and size distribution can vary substantially for different respiratory symptoms and 
several respiratory symptoms can occur simultaneously in influenza infected subjects. Therefore, to thoroughly 
describe the impact of the different respiratory symptoms, a daily monitoring of particles production would be 
necessary. As this information was unavailable in the present study, we used the average respiratory symptom 
score to predict infectiousness.
In summary, we have developed a new model combining infection and symptom dynamics and used unique 
data describing the time course of infection and infectiousness and their variability in healthy adults. Our predic-
tions suggest a high degree of heterogeneity in virus shedding by infected subjects. Our work supports targeting 
mitigation measures at highly infectious individuals to efficiently reduce transmission. Effectiveness of public 
health interventions would depend on accurate identification of highly infectious subjects and on how quickly 
control measures can be applied.
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